Category: Immunology
-
ECCO26 data reinforce long-term durability and real-world impact of AbbVie’s IBD portfolio
Real-world data and three-year trial results show sustained remission and symptom control with Skyrizi and Rinvoq.
-
Inside Immunai’s plan to map the entire immune system
Immunai CEO Noam Solomon details four pivotal studies shaping the future of immunology and oncology research, as part of the ‘Grand Collaboration’.
-
Arkin Bio Ventures III: $100 million fund for transformative therapies
Fund lead, Dr. Pini Orbach, talks about the fund targeting oncology, immunology, inflammation, rare diseases, and their aim to be an active partner from day one.
-
Conquering aging: A bold bid to fix the body’s interconnected systems
Unlimited Bio’s CEO discusses their attempt to achieve something never done before: combining multiple gene therapies in healthy individuals to reverse the ravages of time.
-
Kymera unveils preclinical data for oral autoimmune therapy
The Massachusetts-based company’s oral therapy KT-579 shows promise in preclinical models for lupus, rheumatoid arthritis, and Sjögren’s syndrome.
-
Affibody’s psoriatic arthritis therapy shows long-term promise
New 52-week data for izokibep in psoriatic arthritis show sustained efficacy and a favorable safety profile.
-
UEGW 2025: AbbVie bolsters IBD data for Rinvoq and Skyrizi
New data and lead investigators also reinforce the importance of treating beyond symptoms in Crohn’s disease and ulcerative colitis.
-
Grifols’ Biotest launches Yimmugo immunoglobulin therapy in US market
The US FDA approved the intravenous immunoglobulin (IVIg) therapy for the treatment of primary immunodeficiencies (PID) last year.
-
ECTRIMS 2025: Sanofi spotlights MS therapies and monitoring
Sanofi’s data at ECTRIMS spotlight advances in tolebrutinib, frexalimab, digital biomarkers, and disease burden studies.
-
Santersus wins second FDA Breakthrough Device nod for NucleoCapture
FDA granted the Swiss company’s blood purification technology Breakthrough Device status for severe lupus, marking its second designation.
-
Inside Immunai’s grand collaboration: Mapping the future of immunology
Immunai CEO Noam Solomon discusses the Grand Collaboration Initiative and the future of immune profiling.
-
Revolo fast-tracks oral drug for allergic diseases after promising results
The company’s peptide therapy, ‘1104, shows promise as an oral treatment for allergic diseases, with clinical trials expected to begin in 2026.
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.